Novartis Oncology veterans reunite at Glenmark spinoff Ichnos

Glenmark officially unveiled Ichnos in October. Its headquarters, as well as a development site, are in Paramus, New Jersey, but it maintains R&D sites in Switzerland and India. (Pixabay)

Gabriela Gruia, M.D., who oversaw regulatory affairs for Novartis’ oncology team, is Ichnos Sciences’ new chief development officer. She joins Alessandro Riva, M.D., who left the Swiss pharma for a stint at Gilead in 2017 and took Ichnos’ helm early last year. 

Riva, Novartis’ longtime global oncology development head, arrived at Ichnos before it even had a name—at least one that was publicly known. In March 2019, Glenmark, an Indian company best known for its generics, announced that Riva would take charge of a spinout that would hit the ground running with eight pipeline assets, about 400 staffers and three R&D sites. 

Glenmark officially unveiled Ichnos in October. Its headquarters, as well as a development site, are in Paramus, New Jersey, but it maintains R&D sites overseas, including a biologics research facility and a GMP biologics manufacturing site in Switzerland and a research site dedicated to small molecules in India. Its updated headcount is about 350 employees. 

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

RELATED: Alessandro Riva to leave Gilead to lead Glenmark spinoff 

Half of Ichnos’ programs are in oncology, with the rest split between immunology and pain. The cancer pipeline includes three bispecific antibodies, which could undercut CAR-T therapies by delivering comparable efficacy without the toxicity, logistical complications and associated costs. 

The company’s bispecifics pipeline is led by two treatments in phase 1. It is testing a HER2xCD3 bispecific in HER2-positive cancers and a CD38xCD3 bispecific in multiple myeloma, as well as solid cancers. It expects those trials to read out in 2021. Ichnos also has an eczema candidate in phase 2b, which will turn up data later this year. 

In her new role, Gruia will guide those programs forward, overseeing regulatory sciences, clinical operations, drug safety, clinical pharmacology, biostatistics and clinical outsourcing, Ichnos said in a statement on Wednesday. 

"We are excited to welcome Gabriela to Ichnos Sciences and look forward to her future contributions," Riva said in the statement. "She brings a wealth of industry knowledge and expertise and her recognized leadership skills will be invaluable as we advance our pipeline. In addition, Gabriela's clinical experience enables her to embrace our goal to deliver potentially curative therapies that may change the lives of the patients we aim to treat." 

Suggested Articles

Singapore is planning to outfit each of its 5.7 million residents with a simple wearable device to track people who have been exposed to COVID-19.

The agency delivered its first batch of antibody test results in May, covering a dozen products independently evaluated by the NIH and CDC.

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.